These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1123 related items for PubMed ID: 16011533

  • 1. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF, Price P, French MA.
    HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
    [Abstract] [Full Text] [Related]

  • 2. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA, Ono E, Machado DM, Brunialti M, Succi RC, Salomão R, Kallás EG, de Moraes-Pinto MI.
    Cytometry B Clin Cytom; 2007 Jan 15; 72(1):14-21. PubMed ID: 17041945
    [Abstract] [Full Text] [Related]

  • 3. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.
    Keane NM, Price P, Lee S, Almeida CA, Stone SF, James I, French MA.
    HIV Med; 2004 Nov 15; 5(6):407-14. PubMed ID: 15544692
    [Abstract] [Full Text] [Related]

  • 4. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment.
    Kvale D, Ormaasen V, Kran AM, Johansson CC, Aukrust P, Aandahl EM, Frøland SS, Taskén K.
    AIDS; 2006 Apr 04; 20(6):813-20. PubMed ID: 16549964
    [Abstract] [Full Text] [Related]

  • 5. Cd38 expression on Cd8+ T cells in Human immunodeficiency virus 1-positive adults treated with HAART.
    Beran O, Holub M, Spála J, Kalanin J, Stanková M.
    Acta Virol; 2003 Apr 04; 47(2):121-4. PubMed ID: 14524479
    [Abstract] [Full Text] [Related]

  • 6. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY, Guo FP, Han Y, Qiu ZF, Zuo LY, Li YL, Li TS.
    Chin Med J (Engl); 2009 Oct 20; 122(20):2497-502. PubMed ID: 20079166
    [Abstract] [Full Text] [Related]

  • 7. Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease.
    Bronke C, Palmer NM, Jansen CA, Westerlaken GH, Polstra AM, Reiss P, Bakker M, Miedema F, Tesselaar K, van Baarle D.
    J Infect Dis; 2005 Mar 15; 191(6):873-80. PubMed ID: 15717261
    [Abstract] [Full Text] [Related]

  • 8. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD, Keruly JC.
    Clin Infect Dis; 2007 Feb 01; 44(3):441-6. PubMed ID: 17205456
    [Abstract] [Full Text] [Related]

  • 9. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M, Swiss HIV Cohort Study Group.
    Arch Intern Med; 2003 Oct 13; 163(18):2187-95. PubMed ID: 14557216
    [Abstract] [Full Text] [Related]

  • 10. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy.
    Lim A, Tan D, Price P, Kamarulzaman A, Tan HY, James I, French MA.
    AIDS; 2007 Jul 31; 21(12):1525-34. PubMed ID: 17630546
    [Abstract] [Full Text] [Related]

  • 11. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327
    [Abstract] [Full Text] [Related]

  • 12. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART.
    Marchetti G, Gori A, Casabianca A, Magnani M, Franzetti F, Clerici M, Perno CF, Monforte Ad, Galli M, Meroni L.
    AIDS; 2006 Aug 22; 20(13):1727-36. PubMed ID: 16931937
    [Abstract] [Full Text] [Related]

  • 13. Limited long-term naive CD4+ T cell reconstitution in patients experiencing viral load rebounds during HAART.
    Choremi-Papadopoulou H, Tsalimalma K, Dafni U, Dimitracopoulou A, Kordossis T.
    J Med Virol; 2004 Jun 22; 73(2):235-43. PubMed ID: 15122798
    [Abstract] [Full Text] [Related]

  • 14. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ, Sabin CA, Youle MS, Kinloch-de Loes S, Lampe FC, Madge S, Cropley I, Johnson MA, Phillips AN.
    J Infect Dis; 2004 Nov 15; 190(10):1860-8. PubMed ID: 15499544
    [Abstract] [Full Text] [Related]

  • 15. Regulatory T cells generated during cytomegalovirus in vitro stimulation of mononuclear cells from HIV-infected individuals on HAART correlate with decreased lymphocyte proliferation.
    Jesser RD, Li S, Weinberg A.
    Virology; 2006 Sep 01; 352(2):408-17. PubMed ID: 16782163
    [Abstract] [Full Text] [Related]

  • 16. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A, Galli L, Torti C, D'Arminio Monforte A, Mussini C, Antinori A, Cozzi-Lepri A, Ladisa N, De Luca A, Seminari E, Gianotti N, Lazzarin A.
    Antivir Ther; 2010 Sep 01; 15(2):165-75. PubMed ID: 20386071
    [Abstract] [Full Text] [Related]

  • 17. Cytotoxic CD4 T cells in viral hepatitis.
    Aslan N, Yurdaydin C, Wiegand J, Greten T, Ciner A, Meyer MF, Heiken H, Kuhlmann B, Kaiser T, Bozkaya H, Tillmann HL, Bozdayi AM, Manns MP, Wedemeyer H.
    J Viral Hepat; 2006 Aug 01; 13(8):505-14. PubMed ID: 16901280
    [Abstract] [Full Text] [Related]

  • 18. CD4+ T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8+ T cell activation.
    Benito JM, Lopez M, Lozano S, Ballesteros C, Capa L, Martinez P, Gonzalez-Lahoz J, Soriano V.
    J Infect Dis; 2005 Dec 15; 192(12):2142-6. PubMed ID: 16288380
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads.
    Benveniste O, Flahault A, Rollot F, Elbim C, Estaquier J, Pédron B, Duval X, Dereuddre-Bosquet N, Clayette P, Sterkers G, Simon A, Ameisen JC, Leport C.
    J Infect Dis; 2005 May 15; 191(10):1670-9. PubMed ID: 15838794
    [Abstract] [Full Text] [Related]

  • 20. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A, Cox AE, Shamji MH, John L, Nelson M, Henderson DC, Gotch FM, Gazzard BG, Kelleher P.
    Antivir Ther; 2007 May 15; 12(6):971-5. PubMed ID: 17926652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.